BACKGROUND: Hormonal ablation is the standard of treatment for advanced androgen-dependent prostate cancer. Although tumor regression is usually achieved at first, the cancer inevitably evolves toward androgen-independence, in part because of the development of mechanisms of resistance and in part because at the tissue level androgen withdrawal is not fully attained. Current research efforts are focused on new therapeutic strategies that will increase the effectiveness of androgen withdrawal and delay recurrence. We used a syngeneic pseudo-orthotropic mouse model of prostate cancer to test the efficacy of combining androgen withdrawal with FDA-approved COX-2 inhibitor celecoxib. METHODS: GFP-tagged TRAMP-C2 cells were co-implanted with prostate tissue in the dorsal chamber model and tumors were allowed to establish and vascularize. Tumor growth and angiogenesis were monitored in real-time using fluorescent intravital microscopy (IVM). Androgen withdrawal in mice was achieved using surgical castration or chemical hormonal ablation, alone or in combination with celecoxib (15 mg/kg, twice daily). RESULTS: Celecoxib alone decreased the growth of prostate tumors mostly by inducing mitotic failure, which resulted in increased apoptosis. Surprisingly, celecoxib did not possess significant angiostatic activity. Surgical or chemical castration prevented the growth of prostate tumors and this, on the other hand, was associated with disruption of the tumor vasculature. Finally, androgen withdrawal combined with celecoxib caused tumor regression through decreased angiogenesis and increased mitosis arrest and apoptosis. CONCLUSION: Celecoxib, a relatively safe COX-2-selective anti-inflammatory drug, significantly increases the efficacy of androgen withdrawal in vivo and warrants further investigation as a complement therapy for advanced prostate cancer.
BACKGROUND: Hormonal ablation is the standard of treatment for advanced androgen-dependent prostate cancer. Although tumor regression is usually achieved at first, the cancer inevitably evolves toward androgen-independence, in part because of the development of mechanisms of resistance and in part because at the tissue level androgen withdrawal is not fully attained. Current research efforts are focused on new therapeutic strategies that will increase the effectiveness of androgen withdrawal and delay recurrence. We used a syngeneic pseudo-orthotropic mouse model of prostate cancer to test the efficacy of combining androgen withdrawal with FDA-approved COX-2 inhibitor celecoxib. METHODS: GFP-tagged TRAMP-C2 cells were co-implanted with prostate tissue in the dorsal chamber model and tumors were allowed to establish and vascularize. Tumor growth and angiogenesis were monitored in real-time using fluorescent intravital microscopy (IVM). Androgen withdrawal in mice was achieved using surgical castration or chemical hormonal ablation, alone or in combination with celecoxib (15 mg/kg, twice daily). RESULTS:Celecoxib alone decreased the growth of prostate tumors mostly by inducing mitotic failure, which resulted in increased apoptosis. Surprisingly, celecoxib did not possess significant angiostatic activity. Surgical or chemical castration prevented the growth of prostate tumors and this, on the other hand, was associated with disruption of the tumor vasculature. Finally, androgen withdrawal combined with celecoxib caused tumor regression through decreased angiogenesis and increased mitosis arrest and apoptosis. CONCLUSION:Celecoxib, a relatively safe COX-2-selective anti-inflammatory drug, significantly increases the efficacy of androgen withdrawal in vivo and warrants further investigation as a complement therapy for advanced prostate cancer.
Authors: J L Masferrer; K M Leahy; A T Koki; B S Zweifel; S L Settle; B M Woerner; D A Edwards; A G Flickinger; R J Moore; K Seibert Journal: Cancer Res Date: 2000-03-01 Impact factor: 12.701
Authors: Prasanna Sooriakumaran; Helen M Coley; Stephen B Fox; Patricia Macanas-Pirard; David P Lovell; Alastair Henderson; Chris G Eden; Paul D Miller; Stephen E M Langley; Robert W Laing Journal: Anticancer Res Date: 2009-05 Impact factor: 2.480
Authors: Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney Journal: Cancer Prev Res (Phila) Date: 2010-01
Authors: Samuel K Kulp; Ya-Ting Yang; Chin-Chun Hung; Kuen-Feng Chen; Ju-Ping Lai; Ping-Hui Tseng; Joseph W Fowble; Patrick J Ward; Ching-Shih Chen Journal: Cancer Res Date: 2004-02-15 Impact factor: 12.701
Authors: H-H Sherry Chow; Nathan Anavy; Dawn Salazar; Denise H Frank; David S Alberts Journal: J Pharm Biomed Anal Date: 2004-01-27 Impact factor: 3.935
Authors: Emmanuel S Antonarakis; Elisabeth I Heath; Janet R Walczak; William G Nelson; Helen Fedor; Angelo M De Marzo; Marianna L Zahurak; Steven Piantadosi; Andrew J Dannenberg; Robin T Gurganus; Sharyn D Baker; Howard L Parnes; Theodore L DeWeese; Alan W Partin; Michael A Carducci Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Huarong Huang; Xiao-Xing Cui; Shaohua Chen; Susan Goodin; Yue Liu; Yan He; Dongli Li; Hong Wang; Jeremiah Van Doren; Robert S Dipaola; Allan H Conney; Xi Zheng Journal: Anticancer Res Date: 2014-07 Impact factor: 2.480
Authors: Huaqian Wang; Xiao-Xing Cui; Susan Goodin; Ning Ding; Jeremiah Van Doren; Zhiyun Du; Mou-Tuan Huang; Yue Liu; Xiaodong Cheng; Robert S Dipaola; Allan H Conney; Xi Zheng Journal: Oncol Rep Date: 2013-11-29 Impact factor: 3.906
Authors: Rachana Garg; Jorge M Blando; Carlos J Perez; Priti Lal; Michael D Feldman; Emer M Smyth; Emanuela Ricciotti; Tilo Grosser; Fernando Benavides; Marcelo G Kazanietz Journal: Oncogene Date: 2018-05-16 Impact factor: 9.867